Keywords: Abacavir, USA, FDA, GlaxoSmithKline, Pfizer, ViiV Healthcare, HIV
US FDA finds no increased risk of heart attack with ViiV’s HIV drug abacavir
Article | 03 March 2011
Following an ongoing safety review of abacavir and a possible increased risk of heart attack, the US Food and Drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
